PKO Investment Management Joint Stock Co Sells 15,000 Shares of CVS Health Corporation (NYSE:CVS)

PKO Investment Management Joint Stock Co cut its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 33.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,300 shares of the pharmacy operator's stock after selling 15,000 shares during the period. PKO Investment Management Joint Stock Co's holdings in CVS Health were worth $2,053,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Hopwood Financial Services Inc. bought a new position in CVS Health in the 4th quarter worth approximately $29,000. McIlrath & Eck LLC increased its position in CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after acquiring an additional 174 shares during the period. Financial Perspectives Inc increased its holdings in shares of CVS Health by 137.5% during the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after purchasing an additional 466 shares during the period. Compass Planning Associates Inc bought a new position in shares of CVS Health during the 4th quarter worth about $37,000. Finally, Providence First Trust Co bought a new position in shares of CVS Health during the 4th quarter worth about $42,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Down 0.3%

Shares of CVS Health stock traded down $0.19 during trading on Wednesday, reaching $66.91. The stock had a trading volume of 5,208,935 shares, compared to its average volume of 10,943,564. The stock has a fifty day moving average price of $65.09 and a two-hundred day moving average price of $60.25. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $84.64 billion, a price-to-earnings ratio of 15.97, a P/E/G ratio of 0.96 and a beta of 0.56. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.31 EPS. Sell-side analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.98%. CVS Health's dividend payout ratio is presently 63.48%.

Insiders Place Their Bets

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were purchased at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the transaction, the director now directly owns 12,007 shares in the company, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.22% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Robert W. Baird boosted their price target on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Cowen reissued a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. UBS Group increased their target price on CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a report on Friday, May 2nd. Finally, Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a report on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.